|Videos|September 9, 2022
The future of ibrexafungerp for prevention of recurrent yeast infections
Author(s)Morgan Ebert
Nkechi Azie, MD, MBA, FIDSA, vice president of clinical development and medical affairs at SCYNEXIS, discusses the potential FDA approval of ibrexafungerp (Brexafemme; SCYNEXIS) for the prevention of recurrent vulvovaginal candidiasis.
Advertisement
Note: BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp. Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Updated: CMS proposed G-codes for obstetric billing draw concern from ACOG amid coding transition
2
FDA grants 510(k) clearance to Roche's cobas BV/CV assay
3
Natural Cycles receives FDA clearance for AI-powered fertility algorithm
4
HIV screening, PrEP counseling get stronger ACOG recommendation
5